09/08/2026
Serious fungal infections can be especially challenging to treat in immunocompromised patients.
Now, early phase 3 results for an investigational antifungal therapy are generating interest among infectious disease specialists.
Find out what researchers reported and why the findings may matter:
š https://www.idse.net/a/FjwBAA/f